Table 2.

Tumor characteristics of patients with HCC who underwent treatment with all-oral DAA therapy.

HCC tumor characteristics	HCC group (n = 137)
HCC size (mm), mean, SD
At diagnosis	33.1, 2.9
At treatment	31.2, 2.8
AFP (ng/ml) at diagnosis	751.6, 665.6
Tumor present at HCV treatment, n (%)	64 (47)
Active tumor* present at HCV treatment, n (%)	59 (43)
BCLC stage at HCV treatment, n (%)
0	3 (5)
A	40 (63)
B	14 (22)
C	5 (8)
D	1 (2)
Number of lesions, n (%)
0–1	120 (73)
2–3	27 (20)
4 or more	8 (6)
Metastatic disease, n (%)	2 (1)
Treatments received**
Resection	18 (13)
OLT	77 (56)
Y90	83 (61)
TACE	25 (18)

HCC, hepatocellular carcinoma; AFP, alpha fetoprotein; BCLC, Barcelona Clinic Liver Clinic; OLT, orthotopic liver transplant; Y90, radioembolization; TACE, transcatheter arterial chemoembolization.

^*Active tumor was defined as arterial enhancement and venous washout on tri-phasic CT, contrast-enhanced MRI imaging, or the existence of active tumor onexplant pathology.

^**Patients may have received multiple therapies.